Viral hepatitis in practice - 2010

Current management methods for hepatitis B
Alastair Miller
pp 1-4
Approximately 350 million people worldwide are chronically infected with the hepatitis B virus (HBV) and up to 40% of them will develop potentially serious problems as a result of this infection. These sequelae include cirrhosis, hepatocellular carcinoma (HCC) and requirement for liver transplant. Chronic hepatitis B (CHB) is defined as chronic necroinflammatory disease of the liver caused by persistent infection with HBV.
Comment: Reviewing hepatitis management
Geoffrey Dusheiko
pp 3-3
In this issue, Alastair Miller summarises the current management of the hepatitis B virus (HBV). There are unresolved questions as to the determinants that effect transition between stages of HBV. The clinical significance and possible synergistic effect of occult HBV remains uncertain. HBV treatment targets those with active or progressive disease; such patients are more likely to respond to interferon, and their disease justifies long-term treatment with nucleosides/nucleotides.
Viral hepatitis action in Scotland
Hasnain Jafferbhoy and John F Dillon
pp 5-7
The care of patients with viral hepatitis in Scotland is undergoing a period of radical change, mainly driven by a Scottish government action plan focused on the hepatitis C epidemic in Scotland. This is improving awareness and treatment for all viral hepatitides, including hepatitis B. The lessons for others are what drove policy-makers to action in Scotland, and which factors are particular to Scotland and which are common to all regions.
Recognising outbreaks of hepatitis B
Chee Yung, Gayatri Manikkavasagan and Mary Ramsay
pp 8-11
The timely recognition of potential outbreaks of infectious disease is the first step for triggering an investigation to identify the source and implement appropriate public health measures to limit the spread of infection within the population. This can be particularly challenging for hepatitis B, which has a long incubation period and variable progression rate.

Viral hepatitis in practice was previously supported by Gilead Sciences from 2015 to 2016, by Gilead Sciences and Janssen in 2014, by Gilead Sciences and Roche Products in 2013 and by Gilead Sciences from 2009 to 2012.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Viral hepatitis in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 2041-1162 (Print)  ISSN 2045-7863 (Online)